Key Highlights
- Aleniglipron, Structure Therapeutics’ oral GLP-1 candidate, demonstrated 16.3% placebo-adjusted weight reduction over 44 weeks in the ACCESS II Phase 2 study
- The data surpassed comparable oral GLP-1 therapies from Novo Nordisk (13.6% weight loss) and Eli Lilly (12.4% in Phase 2)
- Continued weight reduction trajectory without plateauing represents a significant advantage over competitor drugs
- Shares of GPCR climbed approximately 10% Monday, reaching $59.80 following the announcement
- The company anticipates an FDA end-of-Phase 2 consultation in Q2 2026, with Phase 3 trials starting H2 2026
Structure Therapeutics unveiled impressive Phase 2 clinical results for aleniglipron, its oral GLP-1 obesity medication, on Monday, propelling GPCR shares up roughly 10% during morning market activity.
Structure Therapeutics Inc., GPCR
The ACCESS II clinical study demonstrated placebo-adjusted weight reduction of 16.3% with the 180 mg dosage and 16.0% with the 240 mg dosage following 44 weeks of treatment. Importantly, neither dosage level exhibited signs of reaching a weight loss plateau.
These outcomes compare favorably against competing therapies. Novo Nordisk’s oral formulation of Wegovy achieved 13.6% weight reduction in Phase 3 trials. Eli Lilly’s orforglipron demonstrated approximately 12.4% in Phase 2 studies, declining to 11.2% in Phase 3.
Previous data released in December had indicated 14.2% weight loss at a reduced dosage. Participants continuing on that initial lower dose for 53 weeks ultimately achieved 16% weight reduction, suggesting sustained therapeutic benefit over extended periods.
Safety and tolerability metrics remained robust. Within the ACCESS Open Label Extension trial, treatment discontinuation due to adverse events occurred in only 2% of participants. The body composition analysis showed a 3.4% discontinuation rate. Structure’s strategy of initiating treatment at a low 2.5 mg dose appears instrumental in maintaining patient adherence.
The compelling results have sparked acquisition speculation. H.C. Wainwright analyst Ananda Ghosh had previously identified aleniglipron this month as “the most acquirable asset in obesity.” The investment firm increased its price target to $114. Citizens maintained a Market Outperform rating while adjusting its target to $113.
Analyst Reactions
Leerink Partners reaffirmed its Outperform rating and $90 price target following the data release. The firm emphasized the favorable tolerability profile and dose-response correlation as critical strengths.
RBC Capital Markets adopted a more cautious stance. Analyst Trung Huynh observed that orforglipron demonstrated comparable Phase 2 performance, only to underperform in Phase 3. He identified an atypically low weight gain rate among placebo participants as a statistical anomaly warranting attention. RBC maintained its Outperform rating on Lilly with a $1,250 price target.
“It’s difficult to characterize these results as meaningfully differentiated from Orfo or oral Wegovy until we get a more robust data set,” Huynh wrote.
What Comes Next
Structure Therapeutics is scheduling an end-of-Phase 2 consultation with the FDA during Q2 2026. Phase 3 clinical trials are projected to commence in the latter half of 2026. Data from both high-dose cohorts in Phase 2 will guide the selection of the optimal dose for advanced trials.
Despite Monday’s rally, the stock remains down 23% year-to-date entering the session, though it has appreciated 155% over the trailing twelve months. At $59.80, GPCR shares trade considerably below Wall Street consensus targets, which span from $90 to $140.
Cantor Fitzgerald had earlier identified this 44-week data milestone as a probable catalyst for share price appreciation. That prediction materialized accurately.
Monday’s price movement elevated GPCR’s market capitalization to approximately $3.81 billion.
